Compare Hyatt Hotels Corporation (H) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Travere Therapeutics Inc. Common Stock — how do they compare? Hyatt Hotels Corporation trades at $160.32 (market cap $15.35B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Hyatt Hotels Corporation is far larger — about 3.1× Travere Therapeutics Inc. Common Stock's market cap, and Hyatt Hotels Corporation pays a 0.37% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 149 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| H | TVTX | |
|---|---|---|
Market Cap | $15.35B | $4.88B |
Volume | 614,954 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $67.52 |
52-Week Low | $135.42 | $26.79 |
Typical Hold Time | 149 Days | 0 Days |
Enterprise Value | $19.26B | $5.01B |
Dividend Yield | 0.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels Corporation (H) trades at $160.32, down 0.53% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows a high P/E ratio of 201.14 but benefits from a strategic collaboration with Delta Air Lines and portfolio expansion. Cash flow trends indicate variability, with a net cash outflow of $227 million in 2025, while revenue grew to $7.10 billion.
The outlook is mixed: analyst consensus is a Moderate Buy with a $197.92 price target, implying 23% upside, but risks include high valuation, debt levels, and net income volatility. Growth drivers include brand expansion and loyalty partnerships, yet investors should monitor execution on profitability and macroeconomic impacts on travel demand.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
